Drugs A - Z
Generic Name: Dicalcium phosphate
CategoryHerbs & Supplements
Aluminum phosphate, calcium phosphate (bone ash, bone phosphate, calcium orthophosphate, calcium phosphate dibasic anhydrous, calcium phosphate dibasic dihydrate, calcium phosphate tribasic, di-calcium phosphate, dicalcium phosphate, dicalcium phosphates, neutral calcium phosphate, precipitated calcium phosphate, tertiary calcium phosphate, tricalcium phosphate, whitlockite), potassium phosphate (dibasic potassium phosphate, dipotassium hydrogen orthophosphate, dipotassium monophosphate, dipotassium phosphate, monobasic potassium phosphate, potassium acid phosphate, potassium biphosphate, potassium dihydrogen orthophosphate), MCI-196 (colestilan), sevelamar (Renagel®), sodium phosphate (anhydrous sodium phosphate, dibasic sodium phosphate, disodium hydrogen orthophosphate, disodium hydrogen orthophosphate dodecahydrate, disodium hydrogen phosphate, disodium phosphate, phosphate of soda, sodium orthophosphate).
Note on terminology: The term "phosphates" in this monograph refers to anhydrous sodium acid phosphate, dibasic sodium phosphate, dipotassium phosphate anhydrous, monobasic potassium acid phosphate, monobasic sodium phosphate, phosphorus, potassium phosphate, sodium biphosphate, and sodium phosphate.
Caution: Do not confuse phosphate salts with toxic substances such as organophosphates, or with tribasic sodium phosphates and tribasic potassium phosphates, which are strongly alkaline.
Phosphorus is a mineral found in many foods, such as milk, cheese, dried beans, peas, colas, nuts, and peanut butter. Phosphate is the most common form of phosphorus. In the body, phosphate is the most abundant intracellular anion. It is critical for energy storage and metabolism, for the utilization of many B-complex vitamins, to buffer body fluids, for kidney excretion of hydrogen ions, for proper muscle and nerve function, and for maintaining calcium balance. Phosphorus is vital to the formation of bones and teeth, and healthy bones and soft tissues require calcium and phosphorus to grow and develop throughout life. Inadequate intake of dietary phosphate can lead to hypophosphatemia (low levels of phosphate in the blood), which can lead to long-term potentially serious complications. Conversely, excess phosphate intake can lead to hyperphosphatemia (high blood phosphorus levels), which can occur particularly in people with impaired kidney function and can lead to potentially serious electrolyte imbalances, adverse effects, or death.
In adults, phosphorus makes up approximately 1% of total body weight It is present in every cell of the body, although 85% of the body's phosphorus is found in the bones and teeth.
Phosphates are used clinically to treat hypophosphatemia, hypercalcemia (high blood calcium levels), as saline laxatives, and in the management of calcium-based kidney stones. They may also be of some benefit to patients with vitamin D resistant rickets, multiple sclerosis, and diabetic ketoacidosis.
EvidenceDISCLAIMER: These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.
Occasional constipation is an U.S. Food and Drug Administration (FDA)-approved use of phosphates in adults and children, both in oral form and as an enema (for example, Fleet Enema). Phosphates are also used to restore bowel activity after surgery.
Hypercalcemia (high blood calcium levels):
Phosphate salts (except for calcium phosphate) are effective in the treatment of hypercalcemia. However, intravenous phosphate for treating hypercalcemia may not be recommended, due to concerns about lowering blood pressure, excessively lowering calcium levels, heart attack, tetany, or kidney failure. Sudden hypotension (low blood pressure), kidney failure, and death have been reported after phosphate infusion.
Hypophosphatemia (low blood phosphorus level):
Hypophosphatemia is an U.S. Food and Drug Administration (FDA)-labeled use of phosphates in adults. Taking sodium phosphate or potassium phosphate is effective for preventing and treating most causes of hypophosphatemia, and should be directed under medical supervision. The underlying cause of the hypophosphatemia should be identified and corrected whenever possible.
Kidney stones (calcium oxalate stones):
Kidney stones (nephrolithiasis) are an U.S. Food and Drug Administration (FDA)-labeled use of phosphates in adults. Taking potassium and sodium phosphate salts orally may help prevent kidney stones in patients with hypercalciuria (high urine calcium levels) and in patients with kidney stones made of calcium oxalate. However, phosphate administration when stones are composed of magnesium-ammonium-phosphate or calcium phosphate may increase the rate of stone formation.
Laxative/bowel preparation for procedures:
This is an U.S. Food and Drug Administration (FDA)-labeled use of phosphates in adults and children. Sodium phosphate taken orally or as an enema may be used for bowel cleansing in preparation for surgery, imaging studies, or endoscopy (for example, Fleet Phospho-soda, Fleet Enema). Phosphates appear to increase peristalsis and cause an influx of fluids into the intestine via osmotic action. Aluminum phosphate is used orally to neutralize gastric acid.
Refeeding syndrome prevention:
After periods of severe malnutrition or starvation (for example, anorexia nervosa), intravenous phosphate may be necessary in order to prevent a refeeding syndrome. Phosphate levels should be closely monitored in such patients.
Bone density (bone metabolism):
Early research shows that high amounts of phosphorus may have negative effects on bone density. This is because phosphorus decreases bone formation and increases bone resorption.
Patients with serious burns may lose phosphate and replacement may be necessary.
The use of prophylactic phosphate therapy in diabetic ketoacidosis is controversial and may be considered, particularly in cases of low phosphate levels.
Hypercalciuria (high urine calcium levels):
Long term, slow release neutral potassium phosphate has been shown to reduce calcium excretion in subjects with absorptive hypercalciuria and appears to be well tolerated. This use of phosphates may be considered to prevent kidney stone formation.
This use of phosphates has not been clearly demonstrated as being beneficial in scientific studies.
Total parenteral nutrition (TPN):
Critically ill patients receiving intravenous feedings often have low phosphate levels. Phosphate levels should be closely monitored in such patients, particularly if kidney function is impaired. Inorganic phosphates avoid incompatibility with calcium in TPN solutions. Addition of phosphate to TPN solutions should be under the supervision of a licensed nutritionist.
Vitamin D resistant rickets:
This use of phosphates has not been clearly demonstrated as being beneficial in scientific studies.
Several studies report that taking phosphates orally does not improve exercise performance.
TraditionWARNING: DISCLAIMER: The below uses are based on tradition, scientific theories, or limited research. They often have not been thoroughly tested in humans, and safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. There may be other proposed uses that are not listed below.
Adults (18 years and older)
The Tolerable Upper Intake Level (UL) for adults ages 19-70 years old is 4 grams per day; for adults 70 years and older the UL is 3 grams per day. The recommended UL in pregnant women is 3.5 grams per day, and in breastfeeding women is 4 grams per day. Phosphate salts should not be administered to patients with hyperphosphatemia and should be used cautiously in those with impaired kidney function.
Doses typically range from 1-3 grams of phosphorous (as a phosphate salt (sodium phosphate or potassium phosphate) or elemental phosphate) per day by mouth for the treatment of calcium oxalate kidney stones, hypercalcemia, or hypophosphatemia. Doses are usually divided and taken throughout the day.
Fleet Enema (118 milliliters) can be used as a laxative when administered rectally. It should be administered as a single daily dose. Laxatives should not generally be used for more than one week. 4-8 grams of sodium phosphate dissolved in water has also been used as a saline laxative (should be taken with plenty of water).
Intravenous phosphate 50 millimoles (sodium 81 millimoles, potassium 9.5 millimoles) over 24 hours has been used during refeeding syndrome when serum phosphate falls below 0.5 millimoles per liter. Phosphate blood levels should be closely followed.
Children (younger than 18 years)
The recommended adequate intake in infants 0-6 months old is 100 milligrams per day (additional phosphorus may be added to infant formulas); the recommended adequate intake in infants 7-12 months old is 275 milligrams per day; the recommended daily intake in children ages 1-3 years old is 460 milligrams per day; the recommended daily intake in children ages 4-8 years old is 500 milligrams per day; the recommended daily intake in children ages 9-18 years old is 1,250 milligrams per day (including pregnant or breastfeeding females).
The Tolerable Upper Intake Level (UL) for infants aged 0-12 months old is not clearly established and the source of intake should be from food and formula only; for children 1-8 years old the UL is 3 grams per day; for children 9-18 years old the UL is 4 grams per day.
Children under 12 years of age should not receive an adult size Fleet Enema. Children 2 to 12 years of age may receive a Fleet Ready-To-Use Enema for children in a single daily dose (2 fluid ounces). Laxatives should not generally be used for more than one week.
Children 5 to 10 years old may receive 5 milliliters Fleet Phospho-soda and should not exceed 10 milliliters in a 24-hour period. Children between 10 to 12 years old may receive 10 milliliters and should not exceed 20 milliliters in a 24-hour period. Children over 12 years old may receive a dose of 20 milliliters and should not exceed 45 milliliters in a 24-hour period. Do not administer to children under five years of age.
Children may also receive intravenous preparations, which should be given under the supervision of a licensed healthcare professional.
SafetyDISCLAIMER: Many complementary techniques are practiced by healthcare professionals with formal training, in accordance with the standards of national organizations. However, this is not universally the case, and adverse effects are possible. Due to limited research, in some cases only limited safety information is available.
Avoid if allergic to any ingredients in phosphorus/phosphate preparations.
Side Effects and Warnings
In general, sodium, potassium, aluminum, and calcium phosphates are likely safe when used orally in recommended doses for short-term periods by people without hyperphosphatemia, impaired kidney function, or other health conditions known to increase the risk of hyperphosphatemia. Sodium phosphate is likely safe when used rectally for short-term periods in otherwise healthy individuals with normal kidney function. Long-term use or high doses used orally or rectally require monitoring of serum electrolytes. Intravenous phosphate is likely safe when used as an U.S. Food and Drug Administration (FDA)-approved prescription drug under medical supervision in people without hyperphosphatemia, impaired kidney function, or other health conditions known to increase the risk of hyperphosphatemia.
Excessive intake of phosphates can cause potentially serious or life-threatening toxicity. Intravenous, oral, or rectal/enema phosphates may cause electrolyte disturbances including hypocalcemia (low calcium blood levels), hypomagnesemia (low magnesium blood levels), hyperphosphatemia (high phosphorus blood levels), or hypokalemia (low potassium levels). Calcification of non-skeletal tissues (particularly in the kidneys), severe hypotension (low blood pressure), dehydration, metabolic acidosis, acute kidney failure, or tetany can occur. Death has been reported in infants or adults with oral, rectal, or intravenous phosphates, particularly in those at increased risk for electrolyte disturbances. Late symptoms may include abdominal pain, vomiting of phosphorescent materials, bloody vomiting and diarrhea, headache, limb aches, tongue coating, foul breath, weakness, and yellow conjunctivae (whites of the eyes). Rare complications may include confusion, convulsions (seizures), headache, dizziness, numbness, tingling, pain, weakness, anxiety, increased thirst, muscle cramps, or fatigue. Abnormal heart rhythms, shortness of breath, foot/leg swelling, and weight gain have been reported.
Nausea or gastrointestinal irritation can occur. A reduction in dosage may be necessary to minimize diarrhea. Potassium acid phosphate may cause dyspepsia in patients with a history of peptic ulcer disease. Aluminum phosphate can cause constipation.
Conditions that may be worsened with excessive phosphorus/phosphate supplementation include burns, heart disease, pancreatitis, rickets, osteomalacia (softening of bones), underactive parathyroid glands (with sodium phosphate or potassium phosphate), underactive adrenal glands (potassium phosphate may increase the risk of hyperkalemia), liver disease, and toxemia of pregnancy.
Pregnancy and Breastfeeding
U.S. Food and Drug Administration (FDA) Pregnancy Category: C.
The Tolerable Upper Intake Level (UL) for phosphorus in pregnant women is 3.5 grams per day, and in breastfeeding women it is 4 grams per day. The recommended daily intake in pregnant or breastfeeding females 18 years old and younger is 1,250 milligrams per day.
Interactions with Drugs
Bile acid sequestrants such as cholestyramine (Questran®) and colestipol (Colestid®) can decrease oral absorption of phosphate. Therefore, oral phosphate supplements should be administered at least one hour before or four hours after these agents.
Corticosteroids may increase urinary phosphorus levels.
Alcohol (ethanol) may increase urinary phosphorus. Wine may enhance absorption of phosphorus (as well as calcium and magnesium).
Medications that may affect electrolyte levels should be used cautiously with phosphates. Examples include: amiloride (Midamor®); angiotensin-converting enzyme (ACE) inhibitors such as benazepril (Lotensin®), captopril (Capoten®), enalapril (Vasotec®), fosinopril (Monopril®), lisinopril (Zestril®, Prinivil®), quinapril (Accupril®), or ramipril (Altace®); cyclosporine; cardiac glycosides (Digoxin®); heparins; anti-inflammatory drugs; potassium-containing agents; salt substitutes; spironolactone (Aldactone®); and triamterene (Dyrenium®).
Interactions with Herbs and Dietary Supplements
Calcium may impair phosphates in the body, and result in calcium deposits in tissues.
Pumpkin seed may increase urine phosphates.
This information is based on a systematic review of scientific literature, edited and peer-reviewed by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com): Ethan Basch, MD, MSc, MPhil (Memorial Sloan Kettering Cancer Center); Dawn Costa, BA, BS (Natural Standard Research Collaboration); Cynthia Dacey, PharmD (Northeastern University); Shaina Tanguay-Colucci, BS (Natural Standard Research Collaboration); Catherine Ulbricht, PharmD (Massachusetts General Hospital); Christine Ulbricht, BS (University of Massachusetts); Wendy Weissner, BA (Natural Standard Research Collaboration); Jen Woods, BS (Natural Standard Research Collaboration).
BibliographyDISCLAIMER: Natural Standard developed the above evidence-based information based on a thorough systematic review of the available scientific articles. For comprehensive information about alternative and complementary therapies on the professional level, go to www.naturalstandard.com. Selected references are listed below.
Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31(4):607-617.
Bredle DL, Stager JM, Brechue WF, et al. Phosphate supplementation, cardiovascular function, and exercise performance in humans. J Appl Physiol 1988;65(4):1821-1826.
Bugg NC, Jones JA. Hypophosphataemia. Pathophysiology, effects and management on the intensive care unit. Anaesthesia 1998;53(9):895-902.
Ehrenpreis ED, Nogueras JJ, Botoman VA, et al. Serum electrolyte abnormalities secondary to Fleet's Phospho-Soda colonoscopy prep. A review of three cases. Surg Endosc 1996;10(10):1022-1024.
Fakiris AJ, Moore DH, Reddy SR, et al. Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study. Gynecol Oncol 2005;96(3):818-823.
Fine A, Patterson J. Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: two cases and a review of the literature. Am J Kidney Dis. 1997;29(1):103-105.
Finn WF, Joy MS. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr Med Res Opin. 2005;21(5):657-664.
Fisher JN, Kitabchi AE. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. J.Clin.Endocrinol.Metab 1983;57(1):177-180.
Garg JP, Chasan-Taber S, Blair A, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum 2005;52(1):290-295.
Heaney RP, Nordin BE. Calcium effects on phosphorus absorption: implications for the prevention and co-therapy of osteoporosis. J Am Coll Nutr 2002;21(3):239-244.
Helikson MA, Parham WA, Tobias JD. Hypocalcemia and hyperphosphatemia after phosphate enema use in a child. J Pediatr Surg 1997;32(8):1244-1246.
Kastenberg D, Chasen R, Choudhary C, et al. Efficacy and safety of sodium phosphate tablets compared with PEG solution in colon cleansing: two identically designed, randomized, controlled, parallel group, multicenter phase III trials. Gastrointest Endosc 2001;54(6):705-713.
Kemi VE, Kärkkäinen MU, Lamberg-Allardt CJ. High phosphorus intakes acutely and negatively affect Ca and bone metabolism in a dose-dependent manner in healthy young females. Br J Nutr. 2006 Sep;96(3):545-52.
Kurihara S, Tsuruta Y, Akizawa T. Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrol Dial Transplant 2005;20(2):424-430.
National Research Council, Food and Nutrition Board. Recommended Dietary Allowances. 10th ed. Washington, D.C.: National Academy Press; 1989:184-187.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.